Literature DB >> 19747993

Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines.

Yoshitaka Kashima1, Mizuho Ikeda, Yasushi Itoh, Yoshihiro Sakoda, Tomoya Nagata, Taichiro Miyake, Kosuke Soda, Hiroichi Ozaki, Misako Nakayama, Hitomi Shibuya, Masatoshi Okamatsu, Hirohito Ishigaki, Hideaki Ishida, Toshihiro Sawai, Yoshihiro Kawaoka, Hiroshi Kida, Kazumasa Ogasawara.   

Abstract

Outbreaks of highly pathogenic avian influenza viruses (HPAIVs) would cause disasters worldwide. Various strategies against HPAIVs are required to control damage. It is thought that the use of non-pathogenic avian influenza viruses as live vaccines will be effective in an emergency, even though there might be some adverse effects, because small amounts of live vaccines will confer immunity to protect against HPAIV infection. Therefore, live vaccines have the advantage of being able to be distributed worldwide soon after an outbreak. In the present study, we found that intranasal administration of a live H5N1 subtype non-pathogenic virus induced antibody and cytotoxic T lymphocyte responses and protected mice against H5N1 HPAIV infection. In addition, it was found that a small amount (100 PFU) of the live vaccine was as effective as 100 microg (approximately 10(10-11) PFU of virus particles) of the inactivated whole particle vaccine in mice. Consequently, the use of live virus vaccines might be one strategy for preventing pandemics of HPAIVs in an emergency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747993     DOI: 10.1016/j.vaccine.2009.08.089

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Cross-protective effect of antisense oligonucleotide developed against the common 3' NCR of influenza A virus genome.

Authors:  Prashant Kumar; Binod Kumar; Roopali Rajput; Latika Saxena; Akhil C Banerjea; Madhu Khanna
Journal:  Mol Biotechnol       Date:  2013-11       Impact factor: 2.695

2.  An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.

Authors:  Ahmad M Haredy; Nobuyuki Takenaka; Hiroshi Yamada; Yoshihiro Sakoda; Masatoshi Okamatsu; Naoki Yamamoto; Takeshi Omasa; Hisao Ohtake; Yasuko Mori; Hiroshi Kida; Koichi Yamanishi; Shigefumi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

3.  A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.

Authors:  Akio Takezaki; Shin-Ichi Tsukumo; Yasuhiro Setoguchi; Julie G Ledford; Hisatsugu Goto; Kazuyoshi Hosomichi; Hisanori Uehara; Yasuhiko Nishioka; Koji Yasutomo
Journal:  J Exp Med       Date:  2019-10-10       Impact factor: 14.307

4.  Potency of a vaccine prepared from A/swine/Hokkaido/2/1981 (H1N1) against A/Narita/1/2009 (H1N1) pandemic influenza virus strain.

Authors:  Masatoshi Okamatsu; Yoshihiro Sakoda; Takahiro Hiono; Naoki Yamamoto; Hiroshi Kida
Journal:  Virol J       Date:  2013-02-06       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.